Recently, Xia et al. [168] employed next-generation sequencing (NGS) in four out of the twelve patients enrolled in the clinical trial using the Ad-p53 vector, Genidicine® [105] and observed reduced p53 expression in the tumours of three patients, all carrying mutations in tumour protein p53 CREB binding protein (CREBBP), cyclin-dependent kinase inhibitor 2A (CDKN2A), LYN proto-oncogene (LYN) and Janus kinase 2 (JAK2) genes. This evidence concerns the gene CDKN2A and neoplasm.